Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26091147 | 0.81 | TSHR (0.54) | TSHRHSD17B10MEN1KMT2AHTT | |
| SCHEMBL16610100 | 0.81 | TSHR (0.53) | TSHRHSD17B10GAAHPGDMEN1 | |
| SCHEMBL11492453 | 0.78 | CASP2 (0.48) | TSHRHSD17B10GAAHPGDMEN1 | |
| SCHEMBL8045914 | 0.77 | TSHR (0.50) | TSHRHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL15399777 | 0.77 | TSHR (0.65) | TSHRRECQLMEN1KMT2ALMNA | |
| SCHEMBL131411 | 0.77 | GAA (0.46) | TSHRHSD17B10GAAHPGDMEN1 | |
| SCHEMBL13376978 | 0.75 | RECQL (0.65) | TSHRRECQLGAAMEN1KMT2A | |
| SCHEMBL2771342 | 0.74 | RECQL (0.63) | TSHRRECQLMEN1KMT2ALMNA | |
| SCHEMBL130047 | 0.73 | GAA (0.44) | TSHRHSD17B10GAAHPGDMEN1 | |
| SCHEMBL9772489 | 0.73 | L3MBTL1 (0.62) | TSHRHSD17B10GAAHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058999-A1 | Substituted Tetrahydropyrrolopyrazine Compounds | GRUENENTHAL GMBH (DE) | 2012-03-08 | — | — | US | disclosed |
| WO-2012028331-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE DERIVATIVES | Grünenthal GmbH (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20120058999-A1 | Substituted Tetrahydropyrrolopyrazine Compounds | GRUENENTHAL GMBH (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058999-A1 | Substituted Tetrahydropyrrolopyrazine Compounds | BDKRB1, BDKRB2, LTB4R | TSHR 975/4885RECQL 2092/4885HSD17B10 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.